As a result, the ruling upholding the patent is now final, according to San Diego-based Vical.
Vijay Samant, Vical’s president and CEO, said: “We are pleased that the Japanese Intellectual Property High Court has confirmed the validity of this fundamental Vical patent.
“This final decision to uphold our Japanese patent bolsters our compelling global patent position in non-viral gene delivery, and we will continue to expand our intellectual property in key world markets.”
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer.